Pregled bibliografske jedinice broj: 180403
Molecular markers in prostate cancer bone metastases
Molecular markers in prostate cancer bone metastases // Journal of tumor marker oncology, 19 (2003), 4; 10-10 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 180403 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Molecular markers in prostate cancer bone metastases
Autori
Tarle, Marko ; Kovačić, Ksenija
Izvornik
Journal of tumor marker oncology (0886-3849) 19
(2003), 4;
10-10
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
metastatic prostate cancer ; CgA ; IL-6 ; IL-11 ; dexamethasone therapy
Sažetak
Hormone refractory prostate cancer is androgen resistant disease and is assigned to chemohormonal/cytotoxic combination therapy. Patients with upgraded IL-6 are given a continous low dose dexamethasone therapy. IL-11. EPO and TPO are drugs of choice (with other cytotoxic agents) in patients with thromobocytopenia. The use of CgA and PAP parameters is also discussed.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
